EOG Resources (NYSE:EOG) was upgraded by analysts at Bernstein to an “outperform” rating in a note issued to investors on Monday. EOG Resources, Inc. (NYSE:EOG) belongs to Basic Materials sector. Its net profit margin is 15.50% and weekly performance is 4.73%. On last trading day company shares ended up $99.55. EOG Resources, Inc. (NYSE:EOG) distance from 50-day simple moving average (SMA50) is 2.11%.
On Nov 06, QUALCOMM, Inc. (NASDAQ:QCOM) isn’t the type of company to go looking for trouble. It’s just that trouble has a way of finding it. As the world’s top supplier for modem chipsets that power smartphones, Qualcomm just wrapped up what should have been a strong fiscal year with a notable boost at the end from the blockbuster launch of Apple ’s new iPhones, which use the company’s chips. QUALCOMM, Inc. (NASDAQ:QCOM) shares decreased -1.87% in last trading session and ended the day at $69.26. QCOM Gross Margin is 60.20% and its return on assets is 16.10%. QUALCOMM, Inc. (NASDAQ:QCOM) quarterly performance is -6.81%.
Sonic (NASDAQ:SONC) Director Robert M. Rosenberg unloaded 25,125 shares of the stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $25.30, for a total transaction of $635,662.50. Following the transaction, the director now directly owns 68,397 shares of the company’s stock, valued at approximately $1,730,444. On 07 November, Sonic Corp. (NASDAQ:SONC) shares decreased -0.60% and was closed at $24.98. SONC EPS growth in last 5 year was 1.00%. Sonic Corp. (NASDAQ:SONC) year to date (YTD) performance is 23.72%.
Furmanite Corporation (NYSE:FRM) named Joseph Milliron as Chief Executive Officer , effective January 1, 2015. Milliron, currently the Company’s President and Chief Operating Officer, will succeed Charles Cox who retires at the end of this year. Furmanite Corporation (NYSE:FRM) ended the last trading day at $6.16. Company weekly volatility is calculated as 8.11% and price to cash ratio as 6.13. Furmanite Corporation (NYSE:FRM) showed a weekly performance of -17.65%.
On Nov. 6 Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that the first patient has been enrolled in a Phase 1 clinical study of MM-398 (nanoliposomal irinotecan injection) in a highly concentrated formulation in patients with recurrent high grade glioma, a type of aggressive brain tumor with poor prognosis. The study is being sponsored and conducted by Dr. Nicholas Butowski, M.D., Associate Professor of Neurological Surgery and Principal Investigator of the study at the University of California, San Francisco, and is supported by research grants from the National Institutes of Health and Merrimack. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) shares decreased -0.80% in last trading session and ended the day at $8.70. MACK return on assets is -66.60%. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) quarterly performance is 29.85%.